Professional Documents
Culture Documents
Global distribution
This graph shows the CVD mortality rate per 100,000 on a global scale. It is more
common in areas Middle East and Russia where rates are between in 444- 861.
Mortality rate in areas of North America and Europe are fairly low between 120238, with higher rates in South America (239-362). This data has been taken in
2011 from World Health Organisation. The reason as to why CVD is lower in
MEDCs such as the UK is due to better research, equipment and medical help
available. This therefore allows them to be able to control it even better.
However, it is increasing in less developed countries, partly as a result of
increasing longevity, urbanisation and lifestyle changes. The World Health
Organisation (WHO) states that more than 60% of the global burden of CHD
occurs in newly developing countries
heart
when
vessels
supplying the
A
attack
occurs
the blood
diseases. In developing countries with high mortality, such as those of subSaharan Africa, low vegetable and fruit intake are also important factors.
It has been reported that there is a heart attack once every 15 minutes. It is also
known that areas of social deprivation have a higher rate of heart disease for
example, Glasgow women have the highest rates of heart attacks in the world.
Economic costs
The economic costs of CHD include the cost to the individual and to the family of
healthcare and time off work, the cost to the government of healthcare and the
cost to the country of lost productivity. In the UK alone, there are 80,500 deaths
due to CHD. Cardiac rehabilitation can cause 427 per treatment episode. Other
treatments such as ACE inhibitors are far cheaper (20 per patient per year). If
all inactive people become active, 10.5% of CHD could be prevented potentially.
However, these can be difficult to quantify, such as:
The direct costs of physical inactivity accounted for estimated US$24
billion in healthcare costs in 1996 WHO
Health problems related to obesity, such as CHD, cost the USA an
estimated US$177 billion a year WHO
Expenditure in OECD countries on CHD medications increased from 9.4%
in 1989 to 11% in 1997 WHO
Cost of healthcare to individual/the government (this will differ depending
which country the patient lives in)
Cost to the individual of having time off work
Cost to the employer
Cost of lost productivity to the country
Health Implications
Before treatment the patient can experience shortness of breath and fatigue with
only light exercise. They can also experience:
Swelling in their feet, ankles, legs and abdomen.
Pain in their chest, shoulders, arms or neck (angina).
The patient may develop a life threatening arrhythmia (irregular heartbeat
that can mean the body does not receive enough blood)
After treatment there may be side effects from the medication
There may also be psychological effects of having a heart attack/nearly
dying/the thought that it could happen again. Some people become
depressed or anxious and are referred to have professional counselling or
relaxation therapy as this can increase the patients risk of having a heart
attack
Lifestyle